Antibody-Drug Conjugates represent a revolutionary class of therapeutics, offering highly targeted cancer treatment with reduced systemic toxicity. The demand for these complex biologics is surging, driven by their precision and efficacy. However, their manufacture demands unparalleled expertise in handling highly potent compounds, precise conjugation chemistry, and rigorous biologic purification — all under stringent Good Manufacturing Practice (GMP) standards.
For over 25 years, Shilpa Medicare has honed its expertise in High Potency API (HPAPI) manufacturing. This deep-rooted knowledge now provides a robust foundation for the new ADC facility. As Sridevi Khambhampaty, CEO of Shilpa Biologicals, highlighted, the facility offers “a uniquely integrated ADC facility built with the knowledge of our existing high potency manufacturing excellence.” This means Shilpa can now provide end-to-end ADC Drug Substance development and manufacturing, encompassing everything from payload synthesis to final purification.
This integrated capability transforms Shilpa into a compelling, cost-competitive Contract Development and Manufacturing Organization (CDMO) partner for global pharmaceutical and biotech companies. Vishnukant Bhutada, Managing Director of Shilpa Medicare, emphasized that this facility, combined with India’s scientific talent, positions the company as “a serious and trusted partner in global ADC Drug Substance manufacturing.”
The commissioning underscores Shilpa’s unwavering commitment to innovation and high-value platforms, solidifying its role in developing high-impact treatments for patients worldwide and enhancing India’s footprint in the global biopharma landscape.